Skip to main content
Orchid Pharma Limited logo

Orchid Pharma Limited — Investor Relations & Filings

Ticker · ORCHPHARMA ISIN · INE191A01027 LEI · 33580076KIKCYSLZVF05 BSE.NS Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2023-11-28 Declaration of Voting R…
Country IN India
Listing BSE.NS ORCHPHARMA

About Orchid Pharma Limited

https://www.orchidpharma.com/

Orchid Pharma Limited is a vertically integrated organization focused on the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company specializes in the anti-infectives segment, with a particular emphasis on cephalosporins and penicillins. Its operations span the entire value chain, including advanced research and development, process chemistry, and large-scale manufacturing. Orchid Pharma maintains facilities that adhere to rigorous international regulatory standards, enabling the supply of high-quality generic formulations and complex molecules to global markets. The company prioritizes innovation in chemical synthesis and formulation development to address complex therapeutic requirements and enhance healthcare outcomes through a robust portfolio of essential medicines.

Recent filings

Filing Released Lang Actions
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a communication to stock exchanges regarding the voting results and scrutinizer report on a postal ballot conducted by Orchid Pharma Limited. It references the SEBI Listing Obligations and Disclosure Requirements Regulations and the Companies Act, indicating it is an official announcement of shareholder voting outcomes. The document does not contain financial statements or detailed financial analysis but rather the results of a shareholder vote. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is short and focused on voting results, not a full report or presentation.
2023-11-28 English
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding the proceedings of a postal ballot conducted by Orchid Pharma Limited. It references the voting process, dates of the postal ballot, regulatory compliance under SEBI and Companies Act, and mentions that the voting results and scrutinizer report will be submitted to stock exchanges and made available on the company's website. The document does not contain the actual voting results but discusses the process and upcoming submission of results. This matches the description of a Declaration of Voting Results & Voting Rights Announcement (DVA), as it pertains to official results from shareholder votes at a general meeting conducted via postal ballot. The document length and content indicate it is not merely an announcement of a report but the proceedings and declaration related to voting results. Therefore, the appropriate classification is DVA with high confidence.
2023-11-27 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is an extensive presentation dated November 20, 2023, from Orchid Pharma Limited. It includes detailed company overview, business strategy, R&D capabilities, market information, competitive advantages, and progress updates. The text mentions a scheduled investor meeting and roadshow, and the presentation is described as being shared with investors and available on the company's website. There are no financial statements or detailed financial results presented, nor is this a regulatory filing or certification. The content is typical of an investor presentation aimed at providing detailed information about the company's business, strategy, and market position to investors. Therefore, the document fits the category of an Investor Presentation (IP).
2023-11-20 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call held by Orchid Pharma Limited on November 6, 2023, discussing the financial performance for the quarter ended September 30, 2023 (Q2 FY24). It includes management's opening remarks, financial results, strategic initiatives, and a Q&A session with analysts. The content is a verbatim record of the call, including participant names, questions, and answers. This matches the definition of a Call Transcript (CT), which is a full text transcript of company conference calls such as earnings calls with Q&A. The document is not a brief earnings release, annual report, or any other filing type. Therefore, the correct classification is CT with high confidence.
2023-11-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement dated November 6, 2023, from Orchid Pharma Limited to stock exchanges. It informs about the availability of the audio recording of an investor call held on the same day to discuss the financial performance for the quarter and half year ended September 30, 2023. The document provides a link to the audio recording but does not contain the transcript or detailed financial data itself. It is a notification about the call recording rather than the call transcript or a financial report. Therefore, the document fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about the availability of the call recording, not the full transcript or report itself.
2023-11-06 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 100% confidence The document is titled 'Investors Presentation Q2 FY24 – Orchid Pharma Limited' and is dated November 6, 2023. It references financial performance for the quarter ended September 30, 2023, and contains detailed financial highlights, charts, and commentary typical of an investor presentation. The text explicitly states it is an 'Investor Presentation' and includes forward-looking statements and disclaimers common in such presentations. The document length is 8492 characters, which is consistent with a detailed presentation rather than a brief announcement. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. It is clearly a presentation prepared for investors focusing on financials, strategy, and market position, matching the definition of an Investor Presentation (IP).
2023-11-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.